Synaerion Therapeutics, Inc. logo

Synaerion Therapeutics, Inc.

Synaerion Therapeutics is a privately held biotechnology company dedicated to the discovery, development and commercialization of novel treatments for Amyotrophic Lateral Sclerosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.synaerion.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
704 Boxwood Court, NJ, 08094
Williamstown
United States
Email
Contact Number
+1 610-761-7311

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In May 2016, Synaerion entered into an exclusive technology sharing licensing agreement with RXi Pharmaceuticals, to utilize RXis technology to further develope RNA-based and small molecule therapeutic for Amyotrophic Lateral Sclerosis.

Synaerion has secured a $1.5 Mn grant from the Flemish Agency for Innovation and Entrepreneurship in Belgium, and is seeking additional $15 Mn in a series A financing to fund its research activities.